• AOI Biosciences raised about JPY 500 million via a third-party allotment and secondary share sale on Sept. 14, 2026.
• SBI Shinsei Corporate Investment took part as an existing investor, making an additional equity investment in the round.
• Funding earmarked to expand the β2GPI “neo-self” antibody test in Japan and overseas, mainly across Asia.
• Proceeds also targeted at scaling quantum-related allosteric drug discovery work using Toshiba’s quantum-inspired optimization solution SQBM+.
• AOI Biosciences said cumulative fundraising reached about JPY 1 billion following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBI Shinsei Corporate Investment Ltd published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.